X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PANACEA BIOTECH - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PANACEA BIOTECH DISHMAN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 155.1 16.2% View Chart
P/BV x 3.3 3.4 97.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
DISHMAN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs374149 251.8%   
Low Rs12982 156.6%   
Sales per share (Unadj.) Rs197.884.1 235.1%  
Earnings per share (Unadj.) Rs21.2-18.3 -115.8%  
Cash flow per share (Unadj.) Rs34.7-6.7 -518.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.983.7 214.9%  
Shares outstanding (eoy) m80.6961.25 131.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.4 92.7%   
Avg P/E ratio x11.9-6.3 -188.1%  
P/CF ratio (eoy) x7.2-17.2 -42.0%  
Price / Book Value ratio x1.41.4 101.4%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3067,074 287.0%   
No. of employees `0000.82.8 30.1%   
Total wages/salary Rs m5,3551,449 369.5%   
Avg. sales/employee Rs Th19,252.71,874.1 1,027.3%   
Avg. wages/employee Rs Th6,459.5527.0 1,225.7%   
Avg. net profit/employee Rs Th2,064.1-407.7 -506.2%   
INCOME DATA
Net Sales Rs m15,9615,154 309.7%  
Other income Rs m265100 265.9%   
Total revenues Rs m16,2265,254 308.9%   
Gross profit Rs m4,103-766 -535.5%  
Depreciation Rs m1,091711 153.4%   
Interest Rs m9441,503 62.8%   
Profit before tax Rs m2,334-2,881 -81.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m1-6 -19.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m62417 3,711.9%   
Profit after tax Rs m1,711-1,121 -152.6%  
Gross profit margin %25.7-14.9 -172.9%  
Effective tax rate %26.7-0.6 -4,581.8%   
Net profit margin %10.7-21.8 -49.3%  
BALANCE SHEET DATA
Current assets Rs m11,0183,810 289.2%   
Current liabilities Rs m9,5178,365 113.8%   
Net working cap to sales %9.4-88.4 -10.6%  
Current ratio x1.20.5 254.2%  
Inventory Days Days110156 71.0%  
Debtors Days Days3567 51.8%  
Net fixed assets Rs m16,30414,480 112.6%   
Share capital Rs m16161 263.3%   
"Free" reserves Rs m12,907903 1,429.2%   
Net worth Rs m14,5165,127 283.1%   
Long term debt Rs m4,1895,832 71.8%   
Total assets Rs m29,80519,433 153.4%  
Interest coverage x3.5-0.9 -378.7%   
Debt to equity ratio x0.31.1 25.4%  
Sales to assets ratio x0.50.3 201.9%   
Return on assets %8.92.0 453.6%  
Return on equity %11.8-21.9 -53.9%  
Return on capital %17.53.6 482.1%  
Exports to sales %24.824.5 101.1%   
Imports to sales %3.710.2 36.7%   
Exports (fob) Rs m3,9561,264 313.0%   
Imports (cif) Rs m596525 113.6%   
Fx inflow Rs m4,9521,539 321.7%   
Fx outflow Rs m697942 74.0%   
Net fx Rs m4,255597 712.4%   
CASH FLOW
From Operations Rs m2,786599 465.0%  
From Investments Rs m-1,529-438 349.1%  
From Financial Activity Rs m-941-303 311.0%  
Net Cashflow Rs m316-141 -223.9%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.6 616.7%  
FIIs % 12.7 1.3 976.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 23.6 93.6%  
Shareholders   46,261 10,259 450.9%  
Pledged promoter(s) holding % 35.8 35.1 102.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  FDC LTD.  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS